The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

January 11, 2024

The expert panel explores the immunological aspects of chronic GVHD, highlighting challenges in simultaneous management, addressing fibrosis, and emphasizing the importance of early intervention in evolving transplant care practices.

January 11, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz distinguish acute from chronic graft-versus-host disease (GVHD), how such distinction has changed over the last decades, and provide an overview of consensus definitions for disease grading.

January 11, 2024

Evandro D. Bezerra, MD, discusses real-world outcomes associated with brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

January 01, 2024

David P. Carbone, MD, PhD, sought to transform lung cancer care and did it—but didn’t anticipate the personal journey it would put him on.

December 20, 2023

Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.

December 10, 2023

Pirtobrutinib continued to showcase clinically meaningful efficacy in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a covalent BTK inhibitor.

December 09, 2023

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

November 03, 2023

Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.

October 25, 2023

Jennifer A. Woyach, MD, elucidates the updated results generated from a phase 2 study of venetoclax monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) whose disease progressed on a prior B-cell receptor inhibitor, expanded on key findings from a genomic analysis from the study, and highlighted what these findings could mean for the CLL treatment paradigm.

September 01, 2023

Dionisia Quiroga, DO, PhD, discusses the emergence of the HER2-low categorization in breast cancer as well as current treatment options for patients with HER2-low disease.

August 31, 2023

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses updated biomarker data from the phase 2 NeoPACT trial of neoadjuvant chemoimmunotherapy in triple-negative breast cancer.

August 24, 2023

Bhuvaneswari Ramaswamy, MD, discusses the importance of real-world data when considering the efficacy of the CDK 4/6 inhibitor palbociclib in hormone receptor–positive breast cancer.

August 10, 2023

John L. Hays, MD, PhD, discusses unmet needs for patients with colorectal cancer and future directions for research in this disease.

August 09, 2023

Bhuvaneswari Ramaswamy, MD, and colleagues highlight treatment for patients with HR-positive breast cancer, discuss the role of pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer, and expand on unmet needs for patients with metastatic HER2-positive breast cancer.

July 24, 2023

Nicole O Williams, MD, discusses unmet needs for patients with HER2-positive breast cancer and potential future research directions in the space.

July 13, 2023

Kai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.

July 02, 2023

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

June 06, 2023

The addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurrence compared with chemoradiotherapy alone as frontline therapy in patients with locally advanced nasopharyngeal carcinoma, according to findings from the phase 3 CONTINUUM trial.

June 05, 2023

Nivolumab plus ipilimumab and chemotherapy continued to show durable benefit at 4 years compared with chemotherapy alone as first-line therapy in patients with advanced non–small cell lung cancer, particularly in the PD-L1–negative and squamous populations.

May 22, 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.